Literature DB >> 11034590

Evidence of a systemic phenomenon for oxidative stress in cholestatic liver disease.

P Ljubuncic1, Z Tanne, A Bomzon.   

Abstract

BACKGROUND: There is considerable evidence indicating that the severity of hepatic damage in individuals with cholestatic liver disease is causally associated with the extent of intrahepatic oxidative stress. Increased levels or accelerated generation of reactive oxygen species and toxic degradative products of lipid peroxidation have been reported in the plasma of individuals with chronic liver disease and animal models of liver disease. Hence, by virtue of their increased presence in the circulation, it is not unreasonable to suppose that they may account for extrahepatic tissue damage in chronic liver disease.
MATERIALS AND METHODS: This hypothesis was tested by determining plasma levels of the ubiquitous antioxidant glutathione (GSH) and lipid peroxides (LP), together with assessment of the extent of lipid peroxidation in the kidney, brain, and heart, in 24 day chronically bile duct ligated (CBDL) rats. The extent of lipid peroxidation in tissues was based on measurement of conjugated dienes, lipid peroxides, and malondialdehyde (MDA) content. Data were compared with identical data collected from unoperated control, pair fed, 24 day bile duct manipulated (sham operated), and pair fed sham operated rats.
RESULTS: In CBDL rats, total and reduced plasma GSH levels were almost half those determined in all control rats. Plasma, kidney, and heart LP levels were significantly increased in CBDL rats compared with controls. MDA levels were significantly higher in the kidney, brain, and heart homogenates prepared from CBDL rats compared with MDA content measured in tissue homogenates prepared from the four groups of control rats.
CONCLUSIONS: Our data show that experimental cholestatic liver disease is associated with increased lipid peroxidation in the kidney, brain, and heart. Hence we have concluded that the oxidative stress in cholestatic liver disease is a systemic phenomenon probably encompassing all tissues and organs, even those separated by the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034590      PMCID: PMC1728111          DOI: 10.1136/gut.47.5.710

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  50 in total

1.  Evidence for altered central noradrenergic function in experimental acute liver failure in the rat.

Authors:  A Michalak; C Rose; P N Buu; R F Butterworth
Journal:  Hepatology       Date:  1998-02       Impact factor: 17.425

Review 2.  Measuring free radical reactions in vivo.

Authors:  A E Holley; K H Cheeseman
Journal:  Br Med Bull       Date:  1993-07       Impact factor: 4.291

Review 3.  An introduction to free radical biochemistry.

Authors:  K H Cheeseman; T F Slater
Journal:  Br Med Bull       Date:  1993-07       Impact factor: 4.291

4.  Marked overproduction of non-cyclooxygenase derived prostanoids (F2-isoprostanes) in the hepatorenal syndrome.

Authors:  J D Morrow; K P Moore; J A Awad; M D Ravenscraft; G Marini; K F Badr; R Williams; L J Roberts
Journal:  J Lipid Mediat       Date:  1993 Mar-Apr

5.  Antioxidant defenses in the bile duct-ligated rat.

Authors:  S Singh; G Shackleton; E Ah-Sing; J Chakraborty; M E Bailey
Journal:  Gastroenterology       Date:  1992-11       Impact factor: 22.682

6.  Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes.

Authors:  R J Sokol; M Devereaux; R Khandwala; K O'Brien
Journal:  Hepatology       Date:  1993-05       Impact factor: 17.425

7.  Intensity of inflammatory damage and serum lipid peroxide concentrations in liver disease.

Authors:  C Fabris; M Pirisi; M P Panozzo; G Soardo; P Toniutto; V Hocza; E Bartoli
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

8.  Comparative binding of bile acids to serum lipoproteins and albumin.

Authors:  S Ceryak; B Bouscarel; H Fromm
Journal:  J Lipid Res       Date:  1993-10       Impact factor: 5.922

9.  Changes of lipid peroxide levels in blood and liver tissue of patients with obstructive jaundice.

Authors:  L Y Tsai; K T Lee; S M Tsai; S C Lee; H S Yu
Journal:  Clin Chim Acta       Date:  1993-04-16       Impact factor: 3.786

10.  Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats.

Authors:  S Krähenbühl; C Talos; B H Lauterburg; J Reichen
Journal:  Hepatology       Date:  1995-08       Impact factor: 17.425

View more
  38 in total

1.  Participation of nuclear factor (erythroid 2-related), factor 2 in ameliorating lithocholic acid-induced cholestatic liver injury in mice.

Authors:  K P Tan; G A Wood; M Yang; S Ito
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  The Protective Effect of Heme Oxygenase-1 against Intestinal Barrier Dysfunction in Cholestatic Liver Injury Is Associated with NF-κB Inhibition.

Authors:  Lijing Zhang; Zhenling Zhang; Bojia Liu; Yanling Jin; Yan Tian; Yi Xin; Zhijun Duan
Journal:  Mol Med       Date:  2017-08-09       Impact factor: 6.354

3.  Effect of cholestasis and NeuroAid treatment on the expression of Bax, Bcl-2, Pgc-1α and Tfam genes involved in apoptosis and mitochondrial biogenesis in the striatum of male rats.

Authors:  Mohammad Nasehi; Sepehr Torabinejad; Mehrdad Hashemi; Salar Vaseghi; Mohammad-Reza Zarrindast
Journal:  Metab Brain Dis       Date:  2019-11-26       Impact factor: 3.584

4.  The traditional ayurvedic medicine, Eugenia jambolana (Jamun fruit), decreases liver inflammation, injury and fibrosis during cholestasis.

Authors:  Ajay C Donepudi; Lauren M Aleksunes; Maureen V Driscoll; Navindra P Seeram; Angela L Slitt
Journal:  Liver Int       Date:  2011-12-30       Impact factor: 5.828

5.  Oxidative stress and antioxidant status in patients with autoimmune liver diseases.

Authors:  Eleanna T Kaffe; Eirini I Rigopoulou; George K Koukoulis; George N Dalekos; Anargyros N Moulas
Journal:  Redox Rep       Date:  2014-08-13       Impact factor: 4.412

6.  Protective effect of low dose of melatonin against cholestatic oxidative stress after common bile duct ligation in rats.

Authors:  Mukaddes Esrefoglu; Mehmet Gül; Memet-Hanifi Emre; Alaattin Polat; Mukadder-Ayse Selimoglu
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

7.  Ursodeoxycholic acid and in vitro vasoactivity of hydrophobic bile acids.

Authors:  A Bomzon; P Ljubuncic
Journal:  Dig Dis Sci       Date:  2001-09       Impact factor: 3.199

8.  Nesfatin-1 alleviates extrahepatic cholestatic damage of liver in rats.

Authors:  Ali Solmaz; Osman Bilgin Gülçiçek; Candaş Erçetin; Hakan Yiğitbaş; Erkan Yavuz; Sinan Arıcı; Can Erzik; Oğuzhan Zengi; Pelin Demirtürk; Atilla Çelik; Fatih Çelebi
Journal:  Bosn J Basic Med Sci       Date:  2016-11-10       Impact factor: 3.363

9.  Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats.

Authors:  M R Ebrahimkhani; S Kiani; F Oakley; T Kendall; A Shariftabrizi; S M Tavangar; L Moezi; S Payabvash; A Karoon; H Hoseininik; D A Mann; K P Moore; A R Mani; A R Dehpour
Journal:  Gut       Date:  2006-03-16       Impact factor: 23.059

10.  Effect of antioxidant treatments on the gut-liver axis oxidative status and function in bile duct-ligated rats.

Authors:  Stelios F Assimakopoulos; Ioannis Maroulis; Nikolaos Patsoukis; Konstantinos Vagenas; Chrisoula D Scopa; Christos D Georgiou; Constantine E Vagianos
Journal:  World J Surg       Date:  2007-10       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.